Fiche publication
Date publication
mai 2018
Journal
La Revue de medecine interne
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BASTIE Jean-Noël
,
Dr ROSSI Cédric
Tous les auteurs :
Rossi C, Bastie JN
Lien Pubmed
Résumé
In this review, we report the main advances of the last years in the four most common lymphomas in France, namely Hodgkin lymphoma, large cell diffuse B lymphoma, follicular lymphoma and mantle cell lymphoma. We have identified consensual practices in first line in France and then distinguished the targeting by new molecules. Thus, we wanted to highlight the problems for each of these four lymphomas and understand the tools used to find solutions. Finally, this review makes it possible to understand to what extent the new molecules (targeted therapies, immunotherapy) make it possible to continuously improve the management of patients with lymphomas. The global dynamics seems to reduce the place of conventional chemotherapies in favor of these new molecules. However, because of the increase in therapeutic possibilities, the challenge remains to find the combination associated with the best risk-benefit ratio.
Mots clés
Hodgkin lymphoma, Immunotherapy, Immunothérapie, Lymphome de Hodgkin, Lymphome non hodgkiniens, Non-hodgkin lymphoma, Targeted drugs, Thérapies ciblées
Référence
Rev Med Interne. 2018 May 22;:
